BFM
DMAAR

Boothbay Fund Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Boothbay Fund Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.3K Sell
529,898
-165,329
-24% -$17.1K ﹤0.01% 2086
2026
Q1 		$42K Buy
695,227
+125,227
+22% +$13.3K ﹤0.01% 1934
2025
Q4 		$107K Hold
570,000
– – ﹤0.01% 1733
2025
Q3 		$124K Hold
570,000
– – ﹤0.01% 1709
2025
Q2 		$68.5K Buy
+570,000
New +$73.3K ﹤0.01% 1333

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Boothbay Fund Management's DMAAR Position: Q2 2026 in Review

Boothbay Fund Management reduced its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 24% in Q2 2026, selling an estimated $17.1K and leaving 529,898 shares worth $58.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2086.

Boothbay Fund Management first reported a position in DMAAR in Q2 2025 and has held it in 5 quarters since. The position peaked at $124K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • Boothbay Fund Management held 529,898 shares of Drugs Made In America Acquisition Corp Rights worth $58.3K as of Q2 2026.
  • Boothbay Fund Management sold 165,329 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $17.1K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2086 holding.
  • Boothbay Fund Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q2 2025 and has held it in 5 quarters since.
  • Boothbay Fund Management's Drugs Made In America Acquisition Corp Rights position peaked at $124K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.